HF
PSTV

HRT Financial’s Plus Therapeutics PSTV Stock Holding History

HRT Financial’s Portfolio PSTV Stock Details PSTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,083
Closed -$96K – 3363
2025
Q1 		$96K Buy
+4,083
New +$114K ﹤0.01% 2154
2023
Q4 		– Sell
-449
Closed -$15K – 2929
2023
Q3 		$15K Buy
+449
New +$24.1K ﹤0.01% 2093

Other funds holding PSTV

Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $50.7M AUM 30.19% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

HRT Financial's PSTV Position: Q2 2025 in Review

HRT Financial sold out of Plus Therapeutics (PSTV) in Q2 2025, closing a stake of 4,083 shares — an estimated $96K sold.

HRT Financial first reported a position in PSTV in Q3 2023 and held it in 2 quarters. The position peaked at $96K in Q1 2025. 18 funds tracked by Wall St. Rank hold PSTV as of Q2 2025.

  • HRT Financial reported no remaining Plus Therapeutics position as of Q2 2025 after selling out during the quarter.
  • HRT Financial sold 4,083 Plus Therapeutics shares in Q2 2025, an estimated $96K.
  • HRT Financial first reported a position in Plus Therapeutics in Q3 2023 and held it in 2 quarters.
  • HRT Financial's Plus Therapeutics position peaked at $96K in Q1 2025.
  • 18 funds tracked by Wall St. Rank held Plus Therapeutics as of Q2 2025.

Based on HRT Financial's 13F filing for Q2 2025, filed 14 Aug 2025.